In-vivo Anticancer Activity of Root and Leaf extract of Jurinea dolomiaea Boiss (Asteraceae) against Ehrlichs Ascites Carcinoma (EAC) Cell Line

Cancer is a type of disease of uncontrolled growth cells. The currently available treatments are radiotherapy, chemotherapy, hormone therapy and surgery, in which all of them have side effects. Due to the adverse side effects, it is challenging to develop new drug for cancer treatment. Hence, the scientists are trying to seek the compounds from natural sources to treat cancer. Therefore, in this present investigation, root and leaf extracts of Jurinea dolomiaea Boiss has subjected to evaluate its anti-proliferative effect along with molecular signaling of apoptosis in Ehrlich ascites carcinoma (EAC) cell line. Jurinea dolomiaea root and leaf extracts exhibit a considerable scavenging activity in comparison to a standard antioxidant BHT. Moreover, root and leaf extracts were able to agglutinate 2% RBC of goat blood at minimum 12.5 g/mL and 50.0 g/mL concentration respectively. Cytotoxic activity was also found in root and leaf extract. In haemocytometic observation, the root and leaf extract exhibit about 62.54±2.41% and 53.96±2.34% cell growth inhibition respectively where as standard anticancer drug Bleomycin showed 79.43±1.92% growth inhibition. Morphological change under fluorescence microscope showed nuclear condensation and fragmentation which are the sign of apoptosis. Therefore, current results depict root extract of Jurinea dolomiaea Boiss have anti-proliferative activity against EAC cell line and can be a good source of anticancer agents to treat cancer.